Clinical Site Services – Sheppard Pratt – Treatment-Resistant Depression

Clinical Site Services – Sheppard Pratt – Treatment-resistant Depression – Clinical Site Services – Sheppard Pratt – Treatment-resistant Depression.

Jamp;Js Promising Pharma Pipeline
Key candidates in the Neuroscience segment include fulranumab (osteoarthritic pain), esketamine (phase II for treatment-resistant depression) and an every-three-month formulation of Invega Sustenna (phase III ongoing for schizophrenia with results … Read more on Zacks.com

Novel Opioid Modulator Acts Quickly to Alleviate Depression
HOLLYWOOD, Florida — Data from a phase 2 study show encouraging results with a new opioid modulator, ALKS 5461, for the treatment of major depression that is resistant to standard therapy, new research suggests. "This would be a drug that, providing … Read more on Medscape